Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Gross Margin (2022 - 2025)

Axsome Therapeutics' Gross Margin history spans 4 years, with the latest figure at 93.71% for Q4 2025.

  • For Q4 2025, Gross Margin rose 256.0% year-over-year to 93.71%; the TTM value through Dec 2025 reached 92.56%, up 120.0%, while the annual FY2025 figure was 92.56%, 120.0% up from the prior year.
  • Gross Margin for Q4 2025 was 93.71% at Axsome Therapeutics, up from 93.03% in the prior quarter.
  • Across five years, Gross Margin topped out at 93.71% in Q4 2025 and bottomed at 88.7% in Q3 2023.
  • The 4-year median for Gross Margin is 91.09% (2025), against an average of 91.08%.
  • The largest annual shift saw Gross Margin plummeted -91bps in 2023 before it soared 325bps in 2024.
  • A 4-year view of Gross Margin shows it stood at 90.6% in 2022, then fell by -1bps to 89.69% in 2023, then rose by 2bps to 91.15% in 2024, then grew by 3bps to 93.71% in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Gross Margin are 93.71% (Q4 2025), 93.03% (Q3 2025), and 91.04% (Q2 2025).